Allergy Therapeutics plc (AGY) Insider Purchases £27,000 in Stock
Allergy Therapeutics plc (LON:AGY) insider Nicolas Wykeman bought 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 27th. The shares were purchased at an average cost of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44).
Shares of Allergy Therapeutics plc (LON:AGY) traded up 9.58% during trading on Wednesday, hitting GBX 19.45. 936,578 shares of the stock were exchanged. The firm has a 50 day moving average of GBX 18.69 and a 200-day moving average of GBX 22.49. Allergy Therapeutics plc has a 52-week low of GBX 17.25 and a 52-week high of GBX 34.82. The stock’s market cap is GBX 108.83 million.
A number of research firms recently weighed in on AGY. Panmure Gordon reaffirmed a “buy” rating and set a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th. Finally, Numis Securities Ltd began coverage on shares of Allergy Therapeutics plc in a report on Wednesday, September 21st. They set a “buy” rating and a GBX 37 ($0.48) target price on the stock.
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.